@riyadlehebi In phase 2, they were looking at all COPD to see if tezepelumab needed to be targeted or not. Answer is it does - if it really works in COPD at all, which remains to be proven in phase 3, but signal from COURSE is interesting
Phase 2 COURSE study just presented at #ATS2024 by Dave Singh @OfficialUoM: tezepelumab did not significantly reduce #COPD exacerbations overall, but trends suggested greater benefits in those with higher Th2 inflammation. Suggests phase 3 study should target this population.
NOTUS trial just presented at #ATS2024 by @suryapbhatt@uabmedicine and published @NEJM: dupilumab reduced exacerbations by 1/3 in #COPD patients with eosinophils >300. Confirms prior BOREAS trial results.
ARISE study just presented at #ATS by @CLDaleyMD@NJHealth: liposomal amikacin as add-on to azithromycin + ethambutol was more likely to achieve microbiological clearance of MAC lung disease at 6 months. Also validated QOL-B RD as a PRO measure in MAC.
Dmitry Rosenberg @uoftmedicine presenting pilot RCT of cognitive-physical home-based pulmonary rehabilitation right now at #ATS2024. Proud to be collaborating with him on this!
🚨@US_FDA stresses at the #ATS2024 session - there is NO technology/device cleared by the agency for counting coughs. The VitaloJAK system mentioned in the presentation is only cleared for audio recording, and NOT for cough counting.
Shows we need a nuanced approach in thinking about how to ensure equity for lung disease patients while considering the implications of practice changes
New study of implications of eliminating race adjustment in PFT equations just presented at #ATS2024 by @JamesADiao: race-neutral interpretation reclassified millions of patients with implications on work, disability eligibility and transplant priority but not clinical outcomes
BICS trial just presented at #ATS2024 by @doclip1 and published @JAMA_current: bisoprolol did not reduce exacerbations in GOLD E #COPD, but did not cause harm either. We should give beta blockers to COPD patients with cardiovascular indications but it won’t help their COPD
UCAP study just presented at #ATS2024 bu Shawn Aaron @uOttawaMed and published @NEJM: case-finding and subspecialist treatment of asthma and COPD reduced healthcare utilization by half and improved quality of life and lung function. We need to find these patients!
ZEPHYRUS-1 just presented at #ATS2024 and published @JAMA_current: pamrevlumab did not slow FVC decline in #IPF. Disappointing that yet another biologic for IPF has failed
How can Canada’s health systems improve care for people with chronic obstructive pulmonary disease? New commentary by @ablazermd and me @CMAJ https://t.co/e9GmRNN3xE